Effects of switching from branched chain amino acids (BCAA) medication to BCAA-enriched nutrient in patients with liver cirrhosis

Effects of switching from branched chain amino acids (BCAA) medication to BCAA-enriched nutrient in patients with liver cirrhosis - Effects of switching from branched chain amino acids (BCAA) medication to BCAA-enriched nutrient in patients with liver cirrhosis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000022902

Enrollment

200

Registered

2016-06-27

Start date

2016-06-27

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cirrhotic patients

Interventions

Switch to 2 packs of BCAA-enriched nutrient mixture in the patients with less than 3.5 g/dl of serum albumin levels despite treatment with 3 packs of BCAA medication. Continue the treatment with 3 pac

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. decompensated cirrhosis 2. serum albumin levels were less than 3.5 g/dl despite treatment with 3 packs of BCAA medication 3. over 20 years-old 4. written informed consent

Exclusion criteria

Exclusion criteria: 1. history of hypersensitivity to amino acid 2. congenital disorders of amino acid metabolism 3. hypoalbuminemia from non-hepatic disease 4. judged inadequate

Design outcomes

Primary

Measure	Time frame
Serum albumin at 6 and 12 months after baseline	—

Secondary

Measure	Time frame
Transthyretin, The molar ratio of branched-chain amino acids(BCAA) to tyrosine (BTR) at 6 and 12 months after baseline	—

Countries

Japan

Contacts

Public ContactKentaro Yoshioka

Fujita Health University Department of Liver, Biliary Tract and Pancreas Diseases

kyoshiok@fujita-hu.ac.jp0562-93-2324

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026